Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Journal
The lancet. Diabetes & endocrinology
Journal Volume
8
Journal Issue
1
Date Issued
2020-01
Author(s)
Heerspink, Hiddo J L
Karasik, Avraham
Thuresson, Marcus
Melzer-Cohen, Cheli
Chodick, Gabriel
Khunti, Kamlesh
Wilding, John P H
Garcia Rodriguez, Luis Alberto
Cea-Soriano, Lucia
Kohsaka, Shun
Nicolucci, Antonio
Lucisano, Giuseppe
Wittbrodt, Eric
Fenici, Peter
Kosiborod, Mikhail
Abstract
Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with type 2 diabetes with or without chronic kidney disease. The aim of this study was to assess whether these benefits extend to patients with type 2 diabetes treated in routine clinical practice.
Type
journal article